Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenomics and gemcitabine.

R Rosell1, M Cobo, D Isla

  • 1Catalan Institute of Oncology, Barcelona, Spain. rrosell@ico.scs.es

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|June 30, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging options and future strategies in immunotherapy for advanced lung squamous-cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Life stage-specific marine migration and spatial behaviour of sea trout (Salmo trutta) from two coastal rivers.

Journal of fish biology·2025
Same author

Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA.

ESMO open·2025
Same author

A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Identification of hazardous organic compounds in e-waste plastic using non-target and suspect screening approaches.

Chemosphere·2024
Same author

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.

ESMO open·2024
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Assessing ERCC1 and BRCA1 mRNA expression in non-small cell lung cancer (NSCLC) can predict patient response to gemcitabine/cisplatin chemotherapy. Low levels of these genes indicate prolonged survival, aiding personalized treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer often presents with metastases or recurs, with limited survival for patients receiving cisplatin-based chemotherapy.
  • Currently, no established predictive factors guide clinical decisions for cisplatin-based chemotherapy response.
  • The nucleotide excision repair system, involving genes like ERCC1, is crucial for repairing platinum-induced DNA damage.

Purpose of the Study:

  • To investigate the predictive role of ERCC1, RRM1, and BRCA1 mRNA expression in advanced non-small cell lung cancer (NSCLC) patients treated with gemcitabine/cisplatin.
  • To determine if these gene expression levels correlate with patient survival outcomes.

Main Methods:

  • Analysis of ERCC1, RRM1, and BRCA1 mRNA expression using paraffin-embedded pretreatment bronchial biopsies.

Related Experiment Videos

  • Correlation of gene expression levels with median survival in advanced NSCLC patients receiving gemcitabine/cisplatin therapy.

    • Main Results:

    • Significantly prolonged median survival was observed in patients with low ERCC1 or RRM1 mRNA levels.
    • Low BRCA1 mRNA expression was also associated with significantly increased survival in the same patient cohort.
    • These findings highlight ERCC1 and BRCA1 as potential predictive biomarkers for gemcitabine/cisplatin treatment.

    Conclusions:

    • Tumor assessment for ERCC1 and BRCA1 mRNA expression is recommended for customizing gemcitabine/cisplatin treatment in advanced NSCLC.
    • This approach may improve patient outcomes by enabling personalized chemotherapy selection based on predictive biomarkers.